Statements (105)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:brand
gptkb:drug |
| gptkbp:bfsLayer |
3
|
| gptkbp:bfsParent |
gptkb:Medi_Wound_Ltd.
|
| gptkbp:activities |
enzymatic debridement
debridement of necrotic tissue |
| gptkbp:advises |
included in burn treatment guidelines
|
| gptkbp:application |
apply to affected area
|
| gptkbp:approves |
gptkb:2016
gptkb:2022 gptkb:FDA gptkb:European_Medicines_Agency |
| gptkbp:availability |
widely available
prescription only available in multiple countries |
| gptkbp:class |
proteolytic enzyme
debriding agent |
| gptkbp:clinical_trial |
gptkb:Fire_Department
ongoing Phase III updated regularly positive outcomes multiple sites published in medical journals burn care debridement of burns completed and ongoing integrated into burn care protocols multiple international trials |
| gptkbp:collaborations |
with various research institutions
|
| gptkbp:competitors |
other burn treatment products
other burn treatments |
| gptkbp:contraindication |
hypersensitivity to bromelain
|
| gptkbp:developed_by |
gptkb:Medi_Wound_Ltd.
|
| gptkbp:dosage_form |
gptkb:tablet
|
| gptkbp:duration |
up to 14 days
varies by patient |
| gptkbp:education |
provided by healthcare professionals
important for use |
| gptkbp:effective_date |
2016-01-20
|
| gptkbp:feedback |
generally positive
|
| gptkbp:formulation |
gptkb:Company
gptkb:tablet |
| gptkbp:frequency |
as needed
once daily |
| gptkbp:healthcare |
gptkb:battle
required |
| https://www.w3.org/2000/01/rdf-schema#label |
Nexo Brid
|
| gptkbp:indication |
eschar removal in burn wounds
eschar removal |
| gptkbp:ingredients |
collagenase
bromelain |
| gptkbp:interacts_with |
none significant
|
| gptkbp:invention |
patented
|
| gptkbp:is_effective_against |
effective in eschar removal
|
| gptkbp:is_reviewed_by |
required
expedited review |
| gptkbp:is_used_for |
debridement of burn wounds
treatment of burn wounds burn wound treatment |
| gptkbp:manager |
topical application
topical |
| gptkbp:manufacturer |
gptkb:Medi_Wound_Ltd.
|
| gptkbp:market |
gptkb:2016
conditional ongoing |
| gptkbp:marketed_as |
gptkb:Medi_Wound_Ltd.
gptkb:United_States multiple countries Nexo Brid brand name |
| gptkbp:origin |
gptkb:Politician
|
| gptkbp:packaging |
single-use vial
single-use container |
| gptkbp:pharmacokinetics |
local action
proteolytic activity monitored by EMA |
| gptkbp:population |
adults and children
|
| gptkbp:price |
varies by region
varies by provider |
| gptkbp:provides_information_on |
recommended for severe burns
|
| gptkbp:publishes |
numerous studies published
|
| gptkbp:receives_funding_from |
public and private sources
supported by grants |
| gptkbp:regulatory_compliance |
approved
marketed EMA approval monitored by FDA |
| gptkbp:research |
ongoing clinical trials
|
| gptkbp:research_and_development |
ongoing studies
|
| gptkbp:safety_features |
generally well tolerated
ongoing post-market surveillance |
| gptkbp:sales |
expanding
|
| gptkbp:scholarships |
available through Medi Wound
|
| gptkbp:side_effect |
rare
local irritation |
| gptkbp:storage |
room temperature
|
| gptkbp:supply_chain |
rare
available in pharmacies managed by Medi Wound |
| gptkbp:traded_on |
gptkb:Nexo_Brid
|
| gptkbp:training |
provided to healthcare providers
|
| gptkbp:treatment |
monitored post-treatment
improved healing |
| gptkbp:type_of_care |
high
|
| gptkbp:type_of_insurance |
may be covered by insurance
|